Roivant Sciences (ROIV) Change in Accured Expenses (2020 - 2026)

Roivant Sciences (ROIV) has reported Change in Accured Expenses for 7 consecutive years, with -$13.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 44.36% year-over-year to -$13.9 million; the trailing twelve-month figure through Jun 2026 stood at -$30.3 million (up 50.33% YoY), and the FY2026 full-year result was $59.3 million, up 689.14% from the prior year.
• Change in Accured Expenses eased to -$13.9 million in Q2 2026 per ROIV's latest filing, from -$3.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $37.6 million in Q3 2023 and bottomed at -$50.0 million in Q2 2023.
• Historically, Change in Accured Expenses has averaged -$6.7 million across 5 years, with a median of -$13.9 million in 2026.
• The widest YoY moves for Change in Accured Expenses: up 91.45% in 2023, down 376.83% in 2023.
• Over 5 years, Change in Accured Expenses stood at $5.7 million in 2022, then plunged by 376.83% to -$15.8 million in 2023, then dropped by 23.58% to -$19.5 million in 2024, then jumped by 80.01% to -$3.9 million in 2025, then plunged by 256.69% to -$13.9 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$13.9 million, -$3.9 million, and $12.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.